ITGB2 and pancreatic neoplasm: Since cancer cells can eventually develop resistance to therapeutic agents18, we treated CD18 pancreatic cancer cells with increasing concentrations of JQ1 over a prolonged period of time to generate CD18 cells resistant to JQ1 (CD18-JQ1R).